Trial · NCT00759291
The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
NCT00759291, Phase 2, Phase 3, Completed, Brigham and Women's Hospital; results first posted 2023-02-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome. Trials, record NCT00759291. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00759291
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Impact of Free Fatty Acid Reduction on Vascular Function in the Metabolic Syndrome
- NCT number
- NCT00759291
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 40 participants, actual
- Lead sponsor
- Brigham and Women's Hospital
- Conditions
- Metabolic Syndrome
- Interventions
- acipimox, Placebo
- First posted
- 2008-09-25
- Last updated
- 2023-02-21
- Results first posted
- 2023-02-21
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Flow Mediated Vasodilation | After 7 days of each treatment. | Brachial artery response to a 5 minute blood pressure cuff-applied ischemic period |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Flow Mediated Vasodilation | After 7 days of each treatment. | percentage of vasodilation | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Flow Mediated Vasodilation | Metabolic Syndrome | Placebo | 9.5 | Standard Deviation 6.5 | percentage of vasodilation |
| Flow Mediated Vasodilation | Control | Placebo | 10.8 | Standard Deviation 4.9 | percentage of vasodilation |
| Flow Mediated Vasodilation | Metabolic Syndrome | Acipimox | 10.5 | Standard Deviation 6 | percentage of vasodilation |
| Flow Mediated Vasodilation | Control | Acipimox | 10.9 | Standard Deviation 6.2 | percentage of vasodilation |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| First Treatment Period | STARTED | Acipimox First, Then Placebo | 17 | |
| First Treatment Period | STARTED | Placebo First, Then Acipimox | 23 | |
| First Treatment Period | COMPLETED | Acipimox First, Then Placebo | 17 | |
| First Treatment Period | COMPLETED | Placebo First, Then Acipimox | 23 | |
| First Treatment Period | NOT COMPLETED | Acipimox First, Then Placebo | 0 | |
| First Treatment Period | NOT COMPLETED | Placebo First, Then Acipimox | 0 | |
| Crossover | STARTED | Acipimox First, Then Placebo | 17 | |
| Crossover | STARTED | Placebo First, Then Acipimox | 23 | |
| Crossover | COMPLETED | Acipimox First, Then Placebo | 17 | |
| Crossover | COMPLETED | Placebo First, Then Acipimox | 23 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Acipimox | 0 | 40 |
| Total, all-cause mortality | Placebo | 0 | 40 |
| Total, other adverse events | Acipimox | 0 | 40 |
| Total, other adverse events | Placebo | 0 | 40 |
| Total, serious adverse events | Acipimox | 0 | 40 |
| Total, serious adverse events | Placebo | 0 | 40 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Acipimox vs Placebo: deaths from any cause | Trial comparisons |
| Acipimox vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00759291
GET https://conductscience.org/api/trials/v1/NCT00759291/registered